Literature DB >> 3224161

Pharmacokinetic analyses with RUGFIT: an interactive pharmacokinetic computer program.

A H Scaf1.   

Abstract

RUGFIT is an interactive computer program to fit polyexponential equations to experimental points without the need of assumptions about the number of exponential terms and without the need of initial parameter estimates. The fitting is performed by iterative stripping minimizing the sum of squared residuals. This procedure leads to multiple model equations describing the profile of the y-value in time, that are compared with the test of Boxenbaum et al. The examples analysed in this paper are: a plasma decay curve after an intravenous bolus injection and one after an oral gift, a dA/dt versus time curve with a lag time and a curve possibly reflecting an entero-hepatic recirculation. The outcomes are, where possible, compared with the outcomes obtained with the computer programs CFT3, NONLIN, and NONLINEAR (SPSS). The latter three programs sometimes run into a local minimum, as the outcomes obtained with RUGFIT were close to the best ones obtained with the other programs. The analyses with RUGFIT show that a choice of an inadequate model equation can lead to a marked error in the value of the area under the curve that may result in a marked error of, for instance, the bioavailability. The procedures of RUGFIT are illustrated in the Appendix. RUGFIT also contains options to calculate microparameters, to simulate dosage regimes, to calculate exponents and intercepts from rate constants and to analyse time effect relationships.

Entities:  

Mesh:

Year:  1988        PMID: 3224161     DOI: 10.1002/bod.2510090502

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  10 in total

1.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

Authors:  J M Wierda; U W Kleef; L M Lambalk; W D Kloppenburg; S Agoston
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

2.  Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.

Authors:  R H Vandenbrom; J M Wierda; S Agoston
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  The pharmacokinetics of beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin in the rat.

Authors:  H W Frijlink; J Visser; N R Hefting; R Oosting; D K Meijer; C F Lerk
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

4.  Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery.

Authors:  J M Wierda; G F Karliczek; R H Vandenbrom; I Pinto; U W Kersten-Kleef; D K Meijer; S Agoston
Journal:  Can J Anaesth       Date:  1990-03       Impact factor: 5.063

5.  Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients.

Authors:  A H Scaf; P H Dunselman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Digoxin infusion versus bolus injection in rapid atrial fibrillation: relation between serum level and response.

Authors:  A J Smit; A H Scaf; L H van Essen; K I Lie; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Pharmacokinetics of pancuronium in patients undergoing coronary artery surgery with and without low dose dopamine.

Authors:  J M Wierda; P J van der Starre; A H Scaf; W D Kloppenburg; J H Proost; S Agoston
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

8.  Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme.

Authors:  E J Franssen; R G van Amsterdam; J Visser; F Moolenaar; D de Zeeuw; D K Meijer
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

9.  Low molecular weight proteins as carriers for renal drug targeting: naproxen coupled to lysozyme via the spacer L-lactic acid.

Authors:  E J Franssen; F Moolenaar; D de Zeeuw; D K Meijer
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

10.  Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.

Authors:  P O Mulder; E G de Vries; D R Uges; A H Scaf; D T Sleijfer; N H Mulder
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.